<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39315175</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2405-8440</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>18</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>Heliyon</Title><ISOAbbreviation>Heliyon</ISOAbbreviation></Journal><ArticleTitle>Effect of amubarvimab-romlusevimab for treatment of severe COVID-19 in intensive care units: A retrospective cohort study.</ArticleTitle><Pagination><StartPage>e37663</StartPage><MedlinePgn>e37663</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e37663</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.heliyon.2024.e37663</ELocationID><Abstract><AbstractText>Amubarvimab-romlusevimab is a commonly recommended antiviral treatment in China for adult patients with mild or moderate SARS-CoV-2 infections, especially for patients with a high risk factor for progression to severe COVID-19. However, its exact efficacy in patients with severe Covid-19 is not yet known.This is a single-center retrospective cohort study, in which we collected the general data, laboratory tests, radiological characteristics, viral conversion status, and prognosis of the disease from patients with COVID-19 hospitalized, from December 2022 to March 2023 in the Department of Critical Care Medicine. The amubarvimab-romlusevimab therapy can reduce the 28-day mortality (29.79 % vs 51.35 %, p = 0.02), and ICU mortality (29.79 % vs 55.41 %, p = 0.006) of severe COVID-19.A 1:1 PSM (Propensity Score Matching) was performed to reduce bias, in order to ensure the two groups were balanced and comparable. In the matched population (n = 47), there were no statistically significant differences between the mAbs (monoclonal antibody)group and the Non-antiviral group in 28-day, and thromboembolic events in COVID-19 patients. The 40-day survival analysis shows that mAbs therapy can improve patient prognosis (HR = 0.45, 95%CI = 0.26-0.76, p = 0.008). However, no significant intergroup difference in the 40-day cumulative viral conversion rate. In a univariate Cox regression analysis, The Amubarvimab - romlusevimab therapy(HR:0.464; CI:[0.252-0.853]; p:0.013) is a protective factor and CRP, PCT, PLT, Lactate, PT, PT-INR, and pt% level at admission were risk factors for clinical prognosis. After including the above covariates, Multifactorial COX regression shows that the Amubarvimab - romlusevimab therapy(HR:0.392; CI:[0.211-0.729]; p:0.003), CRP, Lactate and PT-INR at admission are independent factors for mortality of severe COVID-19. Based on the current data, we conclude that amubarvimab-romlusevimab therapy is beneficial for patients with severe COVID-19.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Qu</LastName><ForeName>Peng</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Guangdong Provincial Key Laboratory of Gastroenterology, Department of Gastroenterology, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lou</LastName><ForeName>Anni</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rong</LastName><ForeName>Dan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Canmin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Guangdong Second Provincial General Hospital, Guangzhou 510317, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Qinglei</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Wanfu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gong</LastName><ForeName>Jiacheng</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Qihan</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhuoer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bathaiian</LastName><ForeName>Luqman Sadat</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>School of Interatibnal Educgtior,Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, Southern Medical University Nanfang Hospital, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Cheng</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Critical Care Medicine, Baiyun Branch, Nanfang Hospital, Southern Medical University, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Heliyon</MedlineTA><NlmUniqueID>101672560</NlmUniqueID><ISSNLinking>2405-8440</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amubarvimab</Keyword><Keyword MajorTopicYN="N">Antibody therapy</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Intensive care Units</Keyword><Keyword MajorTopicYN="N">Romlusevimab</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>11</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>24</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39315175</ArticleId><ArticleId IdType="pmc">PMC11417170</ArticleId><ArticleId IdType="doi">10.1016/j.heliyon.2024.e37663</ArticleId><ArticleId IdType="pii">S2405-8440(24)13694-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu L., Xie C., Qiu M., et al. Characterizing infections in two epidemic waves of SARS-CoV-2 omicron variants: a cohort study in Guangzhou, China. Viruses. 2024;16(4)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11053513</ArticleId><ArticleId IdType="pubmed">38675989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Yang Z., Chen Z.L., et al. When and how will the epidemic of COVID-19 end? Aging Dis. 2022;13(3):641–646.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9116926</ArticleId><ArticleId IdType="pubmed">35656099</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiersinga W.J., Rhodes A., Cheng A.C., Peacock S.J., Prescott H.C. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–793.</Citation><ArticleIdList><ArticleId IdType="pubmed">32648899</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Franchini M., Maggi F., Shoham S. COVID-19 therapeutics. Clin. Microbiol. Rev. 2024;37(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11237566</ArticleId><ArticleId IdType="pubmed">38771027</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23(1):3–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoy S.M. Amubarvimab/romlusevimab: first approval. Drugs. 2022;82(12):1327–1331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396603</ArticleId><ArticleId IdType="pubmed">35997943</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Y.H., Zhan Q.Y., Peng Z.Y., et al. Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: an evidence-based clinical practice guideline (updated version) Mil Med Res. 2020;7(1):41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472403</ArticleId><ArticleId IdType="pubmed">32887670</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Greco M., Zanella A., et al. Risk factors associated with mortality among patients with COVID-19 in intensive care units in lombardy, Italy. JAMA Intern. Med. 2020;180(10):1345–1355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364371</ArticleId><ArticleId IdType="pubmed">32667669</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrando C., Mellado-Artigas R., Gea A., et al. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: a prospective, cohort, multicentre study. Rev. Esp. Anestesiol. Reanim. 2020;67(8):425–437.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7357496</ArticleId><ArticleId IdType="pubmed">32800622</ArticleId></ArticleIdList></Reference><Reference><Citation>Montgomery H., Hobbs F.D.R., Padilla F., et al. Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 2022;10(10):985–996.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9173721</ArticleId><ArticleId IdType="pubmed">35688164</ArticleId></ArticleIdList></Reference><Reference><Citation>Dougan M., Nirula A., Azizad M., et al. Bamlanivimab plus etesevimab in mild or moderate covid-19. N. Engl. J. Med. 2021;385(15):1382–1392.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314785</ArticleId><ArticleId IdType="pubmed">34260849</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis S., Metzendorf M.I., Kuehn R., et al. Nirmatrelvir combined with ritonavir for preventing and treating COVID-19. Cochrane Database Syst. Rev. 2022;9(9)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9487421</ArticleId><ArticleId IdType="pubmed">36126225</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema K.L., Berry K., Streja E., et al. Effectiveness of COVID-19 treatment with nirmatrelvir-ritonavir or molnupiravir among U.S. Veterans: target trial emulation studies with one-month and six-month outcomes. Ann. Intern. Med. 2023;176(6):807–816.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10243488</ArticleId><ArticleId IdType="pubmed">37276589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong C.K.H., Au I.C.H., Lau K.T.K., Lau E.H.Y., Cowling B.J., Leung G.M. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study. Lancet. 2022;400(10359):1213–1222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9539539</ArticleId><ArticleId IdType="pubmed">36216007</ArticleId></ArticleIdList></Reference><Reference><Citation>Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis. 2022;22(5):622–635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8700279</ArticleId><ArticleId IdType="pubmed">34953520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju B., Zhang Q., Ge J., et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020;584(7819):115–119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32454513</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao X., Li D., Liu J., et al. Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study. Virol. J. 2022;19(1):218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9753860</ArticleId><ArticleId IdType="pubmed">36522677</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao X., Zhang Z., Ma J., et al. Randomized, placebo-controlled, single-blind phase 1 studies of the safety, tolerability, and pharmacokinetics of BRII-196 and BRII-198, SARS-CoV-2 spike-targeting monoclonal antibodies with an extended half-life in healthy adults. Front. Pharmacol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9486188</ArticleId><ArticleId IdType="pubmed">36147329</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji Y., Zhang Q., Cheng L., et al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front. Immunol. 2022;13</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9518701</ArticleId><ArticleId IdType="pubmed">36189212</ArticleId></ArticleIdList></Reference><Reference><Citation>Evering T.H., Chew K.W., Giganti M.J., et al. Safety and efficacy of combination SARS-CoV-2 neutralizing monoclonal antibodies amubarvimab plus romlusevimab in nonhospitalized patients with COVID-19. Ann. Intern. Med. 2023;176(5):658–666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10150320</ArticleId><ArticleId IdType="pubmed">37068272</ArticleId></ArticleIdList></Reference><Reference><Citation>Planas D., Saunders N., Maes P., et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022;602(7898):671–675.</Citation><ArticleIdList><ArticleId IdType="pubmed">35016199</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–2040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273827</ArticleId><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Godoy L.C., Goligher E.C., Lawler P.R., Slutsky A.S., Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. CMAJ (Can. Med. Assoc. J.) 2020;192(40):E1156–e1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546749</ArticleId><ArticleId IdType="pubmed">32816822</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M., van der Meer N.J.M., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb. Res. 2020;191:145–147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp S., Coppens M., van Haaps T.F., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18(8):1995–2002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7497052</ArticleId><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuker A., Tseng E.K., Nieuwlaat R., et al. American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19. Blood Adv. 2021;5(3):872–888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7869684</ArticleId><ArticleId IdType="pubmed">33560401</ArticleId></ArticleIdList></Reference><Reference><Citation>Goligher E.C., Bradbury C.A., McVerry B.J., et al. Therapeutic anticoagulation with heparin in critically ill patients with covid-19. N. Engl. J. Med. 2021;385(9):777–789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362592</ArticleId><ArticleId IdType="pubmed">34351722</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawler P.R., Goligher E.C., Berger J.S., et al. Therapeutic anticoagulation with heparin in noncritically ill patients with covid-19. N. Engl. J. Med. 2021;385(9):790–802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone G.W., Farkouh M.E., Lala A., et al. Randomized trial of anticoagulation strategies for noncritically ill patients hospitalized with COVID-19. J. Am. Coll. Cardiol. 2023;81(18):1747–1762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9987252</ArticleId><ArticleId IdType="pubmed">36889611</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor E.H., Marson E.J., Elhadi M., et al. Factors associated with mortality in patients with COVID-19 admitted to intensive care: a systematic review and meta-analysis. Anaesthesia. 2021;76(9):1224–1232.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8444810</ArticleId><ArticleId IdType="pubmed">34189735</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>